IDEAYA Biosciences To Present Results From Multi-Site Global Phase 2 Study Of Neoadjuvant Darovasertib In Primary Uveal Melanoma At 2025 ESMO Meeting

• The presentation will include data from over 90 patients in both the plaque brachytherapy and enucleation-eligible cohorts
• Darovasertib has received U.S. FDA Breakthrough Therapy Designation for use in neoadjuvant uveal melanoma for subjects requiring enucleation
• Initiated a multi-site, global randomized Phase 3 neoadjuvant registrational trial in primary uveal melanoma (OptimUM-10) in Q3 2025

SOUTH SAN FRANCISCO, Calif., July 24, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a leading precision medicine oncology company, today announced that results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology (ESMO) meeting, taking place on October 17-21 in Berlin, Germany. A summary of the data from the abstract will be shared at a future date.